
Membrane type 1 matrix metalloproteinase detection in tumors, using the iodinated endogenous [123I]-tissue inhibitor 2 of metalloproteinases as imaging agent
- Author
- Magali Van Steenkiste (UGent) , Ruth Oltenfreiter (UGent) , Francis Frankenne, Liesbet Vervoort (UGent) , Erik Maquoi, Agnes Noel, Jean-Michel Foidart, Christophe Van De Wiele (UGent) and Filip De Vos (UGent)
- Organization
- Abstract
- Matrix metalloproteinases (MMPs) are principal participants in tumor development. In addition to serve as a useful biochemical marker, MMP expression may also provide a target for the diagnostic in vivo imaging of tumors, using a radiolabeled inhibitor. This study investigates the use of membrane type 1 (MT1)-MMP as target for in vivo tumor diagnosis. Specific binding of the endogenous tissue inhibitor of metalloproteinase-2 (TIMP-2) to MT1-MMP has been previously described. In this study, biodistribution and imaging experiments were performed on MT1-MMP-overexpressing (S.1.5) and control (C.IV.3) tumor-inoculated mice using [I-123]recombinant human TIMP-2 (rhTIMP-2) as radioligand and [I-123]-rhTIMP-1 as control. The expression profile was controlled in vitro and on tumor extracts. rhTIMP-2 as well as rhTIMP-1 were labeled using the Iodogen method and characterized. Biodistribution of [I-123]-rhTIMP-2 showed a tumor uptake of 2.87% +/- 1.58% ID/g at 3 hours postinjection in S.1.5. Tumor values of [I-123]-rhTIMP-1 and [I-123]-rhTIMP-2 evaluated in S.1.5 and C.IV.3, respectively, were significantly lower. Planar imaging revealed significant uptake of [I-123]-rhTIMP-2 in S.1.5 compared with contralateral background areas. This could not be observed in C.IV.3 and with [I-123]-rhTIMP-1 in S.1.5. All tumors were well established (200-800 mg). These results suggest that rhTIMP-2 holds potential for development of radiotracers for in vivo imaging in overexpressing MT1-MMP but not in similar tumors that do not express this protease.
- Keywords
- INVASION, CELLS, EXPRESSION, TIMP-2, ACTIVATION, MT1-MMP, cancer, I-123, ENDOCYTOSIS, molecular imaging, THERAPEUTIC TARGET, 1-MATRIX METALLOPROTEINASE, TISSUE INHIBITOR
Downloads
-
(...).pdf
- full text
- |
- UGent only
- |
- |
- 389.78 KB
-
1261941.pdf
- full text
- |
- open access
- |
- |
- 522.86 KB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-1261941
- MLA
- Van Steenkiste, Magali, et al. “Membrane Type 1 Matrix Metalloproteinase Detection in Tumors, Using the Iodinated Endogenous [123I]-Tissue Inhibitor 2 of Metalloproteinases as Imaging Agent.” CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, vol. 25, no. 5, 2010, pp. 511–20, doi:10.1089/cbr.2010.0789.
- APA
- Van Steenkiste, M., Oltenfreiter, R., Frankenne, F., Vervoort, L., Maquoi, E., Noel, A., … De Vos, F. (2010). Membrane type 1 matrix metalloproteinase detection in tumors, using the iodinated endogenous [123I]-tissue inhibitor 2 of metalloproteinases as imaging agent. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 25(5), 511–520. https://doi.org/10.1089/cbr.2010.0789
- Chicago author-date
- Van Steenkiste, Magali, Ruth Oltenfreiter, Francis Frankenne, Liesbet Vervoort, Erik Maquoi, Agnes Noel, Jean-Michel Foidart, Christophe Van De Wiele, and Filip De Vos. 2010. “Membrane Type 1 Matrix Metalloproteinase Detection in Tumors, Using the Iodinated Endogenous [123I]-Tissue Inhibitor 2 of Metalloproteinases as Imaging Agent.” CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS 25 (5): 511–20. https://doi.org/10.1089/cbr.2010.0789.
- Chicago author-date (all authors)
- Van Steenkiste, Magali, Ruth Oltenfreiter, Francis Frankenne, Liesbet Vervoort, Erik Maquoi, Agnes Noel, Jean-Michel Foidart, Christophe Van De Wiele, and Filip De Vos. 2010. “Membrane Type 1 Matrix Metalloproteinase Detection in Tumors, Using the Iodinated Endogenous [123I]-Tissue Inhibitor 2 of Metalloproteinases as Imaging Agent.” CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS 25 (5): 511–520. doi:10.1089/cbr.2010.0789.
- Vancouver
- 1.Van Steenkiste M, Oltenfreiter R, Frankenne F, Vervoort L, Maquoi E, Noel A, et al. Membrane type 1 matrix metalloproteinase detection in tumors, using the iodinated endogenous [123I]-tissue inhibitor 2 of metalloproteinases as imaging agent. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS. 2010;25(5):511–20.
- IEEE
- [1]M. Van Steenkiste et al., “Membrane type 1 matrix metalloproteinase detection in tumors, using the iodinated endogenous [123I]-tissue inhibitor 2 of metalloproteinases as imaging agent,” CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, vol. 25, no. 5, pp. 511–520, 2010.
@article{1261941, abstract = {{Matrix metalloproteinases (MMPs) are principal participants in tumor development. In addition to serve as a useful biochemical marker, MMP expression may also provide a target for the diagnostic in vivo imaging of tumors, using a radiolabeled inhibitor. This study investigates the use of membrane type 1 (MT1)-MMP as target for in vivo tumor diagnosis. Specific binding of the endogenous tissue inhibitor of metalloproteinase-2 (TIMP-2) to MT1-MMP has been previously described. In this study, biodistribution and imaging experiments were performed on MT1-MMP-overexpressing (S.1.5) and control (C.IV.3) tumor-inoculated mice using [I-123]recombinant human TIMP-2 (rhTIMP-2) as radioligand and [I-123]-rhTIMP-1 as control. The expression profile was controlled in vitro and on tumor extracts. rhTIMP-2 as well as rhTIMP-1 were labeled using the Iodogen method and characterized. Biodistribution of [I-123]-rhTIMP-2 showed a tumor uptake of 2.87% +/- 1.58% ID/g at 3 hours postinjection in S.1.5. Tumor values of [I-123]-rhTIMP-1 and [I-123]-rhTIMP-2 evaluated in S.1.5 and C.IV.3, respectively, were significantly lower. Planar imaging revealed significant uptake of [I-123]-rhTIMP-2 in S.1.5 compared with contralateral background areas. This could not be observed in C.IV.3 and with [I-123]-rhTIMP-1 in S.1.5. All tumors were well established (200-800 mg). These results suggest that rhTIMP-2 holds potential for development of radiotracers for in vivo imaging in overexpressing MT1-MMP but not in similar tumors that do not express this protease.}}, author = {{Van Steenkiste, Magali and Oltenfreiter, Ruth and Frankenne, Francis and Vervoort, Liesbet and Maquoi, Erik and Noel, Agnes and Foidart, Jean-Michel and Van De Wiele, Christophe and De Vos, Filip}}, issn = {{1084-9785}}, journal = {{CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS}}, keywords = {{INVASION,CELLS,EXPRESSION,TIMP-2,ACTIVATION,MT1-MMP,cancer,I-123,ENDOCYTOSIS,molecular imaging,THERAPEUTIC TARGET,1-MATRIX METALLOPROTEINASE,TISSUE INHIBITOR}}, language = {{eng}}, number = {{5}}, pages = {{511--520}}, title = {{Membrane type 1 matrix metalloproteinase detection in tumors, using the iodinated endogenous [123I]-tissue inhibitor 2 of metalloproteinases as imaging agent}}, url = {{http://doi.org/10.1089/cbr.2010.0789}}, volume = {{25}}, year = {{2010}}, }
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: